Effect of vitamin D supplementation on serum C-reactive protein level: a meta-analysis of randomized controlled trials

  • Zahra Yari PhD student, Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Samira Ebrahimof Mail Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Keywords:
CRP, inflammation, meta-analysis, cholecalciferol, vitamin D

Abstract

Objective: Vitamin D may have anti-inflammatory actions however; there is no consensus on the effects of vitamin D supplementation on C-reactive protein (CRP) level in randomized clinical trials. In a systematic review and meta-analysis, we hypothesized that vitamin D supplementation would reduce serum CRP levels.
Materials and Methods: A systematic research of randomized controlled trials has been conducted on MEDLINE and EMBASE through PubMed, Scopus, and completed by a manual review of the literature up from January 2000 to May 2015. Pooled effect estimated by using random-effect model and heterogeneity was assessed by Cochran’s Q and I2 tests.
Results: Of 157 potentially relevant studies we found in a systematic search, 20 clinical trials met the inclusion criteria. Mean baseline CRP levels in the intervention group and in the control group were 3.5±2.6 and 3.3±2.3 mg/L, respectively. Mean duration of the studies were 29.0±30.2.0 (SD) weeks (8 to 144 weeks). Doses of vitamin D3 supplementation varied between 200 to 57142 IU/day. Pooled analysis showed a non-significant increase of 0.04 mg/L (95% CI, −0.12 to 0.21; p < 0.61), with no evidence of heterogeneity (I2 = 17.8%, p < 0.17).
Conclusion: The results of this meta-analysis showed that vitamin D supplementation may not be effective for the reduction of CRP. However, a more accurate estimate of the effect requires further large and well-designed clinical trials.

References

Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr. 2008;87(4):1080S-6S.

Holick MF. Vitamin D deficiency. New England Journal of Medicine. 2007;357(3):266-81.

Adams JS, Hewison M. Update in vitamin D. The Journal of Clinical Endocrinology & Metabolism. 2010;95(2):471-8.

Guillot X, Semerano L, Saidenberg-Kermanac’h N, Falgarone G, Boissier M-C. Vitamin D and inflammation. Joint Bone Spine. 2010;77(6):552-7.

May E, Asadullah K, Zugel U. Immunoregulation through 1, 25-dihydroxyvitamin D 3 and its analogs. Current Drug Targets-Inflammation & Allergy. 2004;3(4):377-93.

Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation. 2003;107(3):499-511.

van Etten E, Mathieu C. Immunoregulation by 1, 25-dihydroxyvitamin D 3: basic concepts. The Journal of steroid biochemistry and molecular biology. 2005;97(1):93-101.

Shea MK, Booth SL, Massaro JM, Jacques PF, D'Agostino RB, Dawson-Hughes B, et al. Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. American journal of epidemiology. 2008;167(3):313-20.

Michos ED, Streeten EA, Ryan KA, Rampersaud E, Peyser PA, Bielak LF, et al. Serum 25-hydroxyvitamin d levels are not associated with subclinical vascular disease or C-reactive protein in the old order amish. Calcified tissue international. 2009;84(3):195-202.

Amer M, Qayyum R. Relation between serum 25-hydroxyvitamin D and C-reactive protein in asymptomatic adults (from the continuous National Health and Nutrition Examination Survey 2001 to 2006). The American journal of cardiology. 2012;109(2):226-30.

Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care. 2007;30(4):980-6.

Bjorkhem-Bergman L, Nylen H, Norlin AC, Lindh JD, Ekstrom L, Eliasson E, et al. Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4beta-hydroxycholesterol in a high-dose vitamin D supplementation study. Drug Metab Dispos. 2013;41(4):704-8. Epub 2013/02/07.

Liefaard MC, Ligthart S, Vitezova A, Hofman A, Uitterlinden AG, Kiefte-de Jong JC, et al. Vitamin D and C-Reactive Protein: A Mendelian Randomization Study. PLoS ONE. 2015;10(7):e0131740.

Picot J, Hartwell D, Harris P, Mendes D, Clegg A, Takeda A. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist. 2012.

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12. Epub 1996/02/01.

Beilfuss J, Berg V, Sneve M, Jorde R, Kamycheva E. Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects. Cytokine. 2012;60(3):870-4.

Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr. 2005;135(2):317-22.

Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84(1):18-28.

Von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient-a randomised, placebo-controlled trial. British Journal of Nutrition. 2010;103(4):549-55.

Wood AD, Secombes KR, Thies F, Aucott L, Black AJ, Mavroeidi A, et al. Vitamin D 3 supplementation has no effect on conventional cardiovascular risk factors: A parallel-group, double-blind, placebo-controlled RCT. Journal of Clinical Endocrinology and Metabolism. 2012;97(10):3557-67.

Rahimi-Ardabili H, Pourghassem Gargari B, Farzadi L. Effects of vitamin D on cardiovascular disease risk factors in polycystic ovary syndrome women with vitamin D deficiency. Journal of Endocrinological Investigation. 2013;36(1):28-32.

Sadiya A, Ahmed SM, Carlsson M, Tesfa Y, George M, Ali SH, et al. Vitamin D supplementation in obese type 2 diabetes subjects in Ajman, UAE: a randomized controlled double-blinded clinical trial. European Journal of Clinical Nutrition. 2014.

Chandler PD, Scott JB, Drake BF, Ng K, Manson JE, Rifai N, et al. Impact of vitamin D supplementation on inflammatory markers in African Americans: results of a four-arm, randomized, placebo-controlled trial. Cancer Prev Res (Phila). 2014;7(2):218-25. Epub 2013/12/12.

Gepner AD, Ramamurthy R, Krueger DC, Korcarz CE, Binkley N, Stein JH. A prospective randomized controlled trial of the effects of Vitamin D supplementation on cardiovascular disease risk. PLoS ONE. 2012;7(5).

Barnes MS, Horigan G, Cashman KD, Hill TR, Forsythe LK, Lucey AJ, et al. Maintenance of wintertime vitamin D status with cholecalciferol supplementation is not associated with alterations in serum cytokine concentrations among apparently healthy younger or older adults. Journal of Nutrition. 2011;141(3):476-81.

Muldowney S, Lucey AJ, Hill TR, Seamans KM, Taylor N, Wallace JM, et al. Incremental cholecalciferol supplementation up to 15 mug/d throughout winter at 51-55 degrees N has no effect on biomarkers of cardiovascular risk in healthy young and older adults. J Nutr. 2012;142(8):1519-25. Epub 2012/06/29.

Witham MD, Dove FJ, Khan F, Lang CC, Belch JJF, Struthers AD. Effects of Vitamin D supplementation on markers of vascular function after myocardial infarction - A randomised controlled trial. International Journal of Cardiology. 2013;167(3):745-9.

Sharifi N, Amani R, Hajiani E, Cheraghian B. Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine. 2014;47(1):70-80.

Chen N, Wan Z, Han S-F, Li B-Y, Zhang Z-L, Qin L-Q. Effect of vitamin D supplementation on the level of circulating high-sensitivity C-reactive protein: a meta-analysis of randomized controlled trials. Nutrients. 2014;6(6):2206-16.

BHALLA AK, AMENTO EP, CLEMENS TL, HOLICK MF, KRANE SM. Specific high-affinity receptors for 1, 25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. The Journal of Clinical Endocrinology & Metabolism. 1983;57(6):1308-10.

Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1, 25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr. 2004;80(6):1717S-20S.

Adorini L, Penna G, Fibbi B, Maggi M. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. Annals of the New York Academy of Sciences. 2010;1193(1):146-52.

Eleftheriadis T, Antoniadi G, Liakopoulos V, Antoniadis N, Stefanidis I, Galaktidou G. Vitamin D receptor activators and response to injury in kidney diseases. J Nephrol. 2010;23(5):514-24.

Chen Y, Kong J, Sun T, Li G, Szeto FL, Liu W, et al. 1, 25-Dihydroxyvitamin D 3 suppresses inflammation-induced expression of plasminogen activator inhibitor-1 by blocking nuclear factor-κB activation. Archives of biochemistry and biophysics. 2011;507(2):241-7.

Published
2017-03-28
How to Cite
1.
Yari Z, Ebrahimof S. Effect of vitamin D supplementation on serum C-reactive protein level: a meta-analysis of randomized controlled trials. J Nutr Sci & Diet. 3(1).
QRcode
Section
Review Article(s)